Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.

Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · Jun 10, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how a medication called semaglutide affects a special type of fat in the body known as brown adipose tissue (BAT), which helps burn calories and generate heat. The researchers want to see if taking semaglutide can increase the activity of BAT and boost the body's metabolism, which may help with weight loss in people who are obese. The trial will involve taking pictures of BAT activity using an infrared camera at different times during the treatment.

To participate in this trial, you need to be over 18 years old and planning to start semaglutide for weight loss. Both men and post-menopausal women can join, but certain health conditions may exclude you, such as having had neck surgery or currently being on certain medications that affect blood sugar. If you enroll, you can expect to have your BAT activity monitored before starting the medication and again at specific points during your treatment. Importantly, the trial does not cover the cost of the semaglutide medication itself.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects scheduled to start semaglutide for weight loss (drug not provided by or paid for by the study)
• • \>18 years of age and willing to participate
• • Male or post-menopausal females
• Exclusion Criteria:
• • History of prior neck surgery and /or neck irradiation
• • Use of beta blocker agents
• • Use of any other glucose lowering medication
• • History of neuropathic disorders (e.g. diabetic neuropathy)
• • Diabetic patients
• • Individuals without normal thyroid function
• • Individuals with cancer
• • Any significant chronic disease or renal, hepatic or endocrine disease
• • Current smokers
• • Inability of patient to provide consent either for medical reasons or psychiatric reasons